Building the Future of the
Beckley Waves funds, supports, and mentors the emerging leaders, entrepreneurs, and partnerships working to create the operational infrastructure of a global psychedelic ecosystem–rooted in Amanda Feilding’s work–with it’s core mission to grow psychedelic access
Mission
Incubate. Invest. Impact.
Incubate
We found new companies that deliver products and services targeting high-impact and lawful opportunities in the emerging psychedelic marketplace.
Invest
We invest in pioneering, mission-aligned start-ups working to transform the delivery of psychedelic-assisted treatments, therapies, and experiences.
Impact
We are working to build, expand, and strengthen the foundational infrastructure that will support the responsible and lawful use of psychedelics to advance human wellbeing and consciousness.
Ethos
Safety. Access. Responsibility.
Safety
We are committed to the safe and lawful use of professionally administered psychedelic treatments in clinical, therapeutic, or spiritual settings.
Access
We focus on early-stage providers, platforms & products enabling equitable, lawful access to psychedelic treatments, therapies, or experiences.
Responsibility
We invest in high-integrity leaders and companies dedicated to ethical, legal, and responsible practices that benefit individuals, society, and the natural world.
History
Building on a Legacy
Over the past six decades, Amanda Feilding, our co-founder and chair, has been at the forefront of a global movement that is reshaping humanity’s understanding of the role that psychoactive compounds and treatments can play in human health, development, and wellbeing.
Since its creation by Feilding in 1998, the Beckley Foundation has initiated and funded scientific research and clinical trials that have led to groundbreaking discoveries in human cognition and the treatment of mental-health disorders, including pioneering the use of brain-imaging technologies that have begun to unravel the neurophysiological mechanisms underlying altered states of consciousness.
In recent years, the research spearheaded and supported by the Beckley Foundation has not only reawakened worldwide interest in the medicinal, therapeutic, and spiritual applications of psychedelics, but it has inspired and motivated advocates to challenge outdated and obstructive drug policies that are undermining potential advancements in public health and denying millions of people access to safe and effective treatments.
More recently, Feilding also co-founded Beckley Psytech, a private company working to develop a pipeline of psychedelic compounds and licensed pharmaceutical medicines that can be used in the treatment of neurological and psychiatric disorders.
Now, Beckley Waves, a venture studio, will carry on Feilding’s legacy by supporting the emerging leaders and companies that are actively building a global infrastructure to enable safe, legal, and responsible access to psychedelic medicines and psychedelic-assisted therapies.
